FindTrial
Sign In

The study of efficacy and safety of Roxadustat in anemia patients after kidney transplantation

The study of efficacy and safety of Roxadustat in anemia patients after kidney transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057485
Enrollment
Unknown
Registered
2022-03-14
Start date
2022-03-10
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kindey transplant

Interventions

Group 1:Roxadustat
Group 2:Recombinant human erythropoietin

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who received allograft kidney transplantation for the first time in our hospital; 2. Aged between 18 and 65 years; 3. Patients diagnosed with anemia after renal transplantation (diagnostic criteria: Hb<13g/dl for men and Hb<12g/dl for women).

Exclusion criteria

Exclusion criteria: 1. Combined with thalassemia, aplastic anemia and other hematological diseases; 2. Patients with uncorrected nutritional anemia; 3. ABO blood group out of renal transplant recipients; 4. The postoperative delayed graft function healing (of graft function, DGF); 5. Patients with tumors and autoimmune diseases; 6. Patients who could not be regularly followed up in our hospital and lacked laboratory data; 7. Patients with gastrointestinal bleeding.

Design outcomes

Primary

MeasureTime frame
hemoglobin;—

Secondary

MeasureTime frame
serum creatinine;—

Countries

China

Contacts

Public ContactShi Yunying
yyshi0130@163.com+86 18980605862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026